TY - JOUR
T1 - Teriparatide therapy for bisphosphonate-related osteonecrosis of the jaw associated with dental implants
AU - Doh, Re Mee
AU - Park, Hye Jeong
AU - Rhee, Yumie
AU - Kim, Hyun Sil
AU - Huh, Jisun
AU - Park, Wonse
N1 - Publisher Copyright:
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2015/4/4
Y1 - 2015/4/4
N2 - This report describes a case of teriparatide (TPTD) therapy for bisphosphonate (BP)-related osteonecrosis of the jaw induced after implant placement. A 75-year-old woman taking oral BP was referred with uncontrolled osteonecrosis of the mandible related to the implant placement. With conservative treatment, BP was suspended and daily subcutaneous injections of 20 m/d TPTD were started. After 4 months of the therapy, fixture removal and sequestrectomy were performed. Histological analysis revealed necrotic lamellar bone and empty osteocytic lacunae. In contrast, multiple irregular reversal lines of the lamellar bone and active osteoblasts were noted adjacent to the lesion. There was a significant increase in serum C-terminal telopeptide cross-link of type 1 collagen and serum osteocalcin after commencement of the therapy. After 7 months off therapy, the serum levels of the 2 markers remained at a high level compared with the baseline.
AB - This report describes a case of teriparatide (TPTD) therapy for bisphosphonate (BP)-related osteonecrosis of the jaw induced after implant placement. A 75-year-old woman taking oral BP was referred with uncontrolled osteonecrosis of the mandible related to the implant placement. With conservative treatment, BP was suspended and daily subcutaneous injections of 20 m/d TPTD were started. After 4 months of the therapy, fixture removal and sequestrectomy were performed. Histological analysis revealed necrotic lamellar bone and empty osteocytic lacunae. In contrast, multiple irregular reversal lines of the lamellar bone and active osteoblasts were noted adjacent to the lesion. There was a significant increase in serum C-terminal telopeptide cross-link of type 1 collagen and serum osteocalcin after commencement of the therapy. After 7 months off therapy, the serum levels of the 2 markers remained at a high level compared with the baseline.
UR - http://www.scopus.com/inward/record.url?scp=84926192269&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84926192269&partnerID=8YFLogxK
U2 - 10.1097/ID.0000000000000232
DO - 10.1097/ID.0000000000000232
M3 - Article
C2 - 25734949
AN - SCOPUS:84926192269
VL - 24
SP - 222
EP - 226
JO - The International journal of oral implantology : implantologist
JF - The International journal of oral implantology : implantologist
SN - 1056-6163
IS - 2
ER -